Today's Trend
Edesa Biotech, Inc. (NASDAQ:EDSA) — Shares moved lower today despite several favorable developments. Investors should weigh a materially positive Phase 3 trial readout and fresh analyst support against the company’s small market cap, continued expected losses and typical microcap liquidity/volatility.
- Phase 3 ARDS trial: Edesa’s EB05 reportedly lowered risk of death by ~25% in a Phase 3 acute respiratory distress syndrome (ARDS) study — a clinically meaningful mortality signal that could materially improve the drug’s regulatory and commercial outlook if confirmed. EB05 Reduces Risk of Death 25% in Phase 3 ARDS Trial
- Analyst upgrades and reiterated Buy: HC Wainwright reiterated a "Buy" and $5 price target while raising near-term estimates — Q4 2025 EPS to ($0.28) from ($0.31), FY2025 to ($1.22) from ($1.29) and FY2026 to ($1.16) from ($1.38) — signaling increased analyst confidence after recent data. HC Wainwright Reaffirms "Buy" Rating for Edesa Biotech
- Analyst cadence: HC Wainwright also released a set of quarterly FY2026 forecasts (multiple quarters at roughly ($0.30)/quarter and Q4 at ($0.26)), reflecting a path to gradually smaller losses but still negative earnings in the near term. Edesa Biotech Receives a Buy from H.C. Wainwright
- Risk/valuation: Edesa remains a microcap with a small market capitalization, negative consensus EPS (expected losses for FY2025–26) and low average liquidity — factors that increase downside risk, dilution concerns and share-price volatility even after positive data.
Bottom line for investors: the Phase 3 mortality result and HC Wainwright’s raised estimates/Bu y rating are constructive for valuation and upside potential, but the stock’s small-cap profile, ongoing losses and low liquidity likely explain near-term selling/underperformance despite the positive news.